Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call on May 10, 2022, at 8:00 a.m. ET to share financial results for Q1 ended March 31, 2022, and provide a business update. Investors can access the call by dialing (800) 343-5172 domestically or (203) 518-9814 internationally, with conference ID AVIRQ122. A live audio webcast and slide presentation will be available on Atea's website.

Atea focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C.

Positive

• Focused on developing oral antiviral therapies for life-threatening viral diseases.
• Plans to enhance its pipeline with additional antiviral products.

Negative

• None.

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to report financial results for the first quarter ended March 31, 2022, and to provide a business update.

To access the live conference call, please dial (800) 343-5172 (domestic) or (203) 518-9814 (international) at least five minutes prior to the start time and refer to conference ID: AVIRQ122. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company's website, www.ateapharma.com. An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the development of orally-available antiviral agents for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus (HCV), dengue virus and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing of Atea’s earnings call for the quarter ended March 31, 2022. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

FAQ

What are Atea Pharmaceuticals' financial results for the first quarter of 2022?

Atea Pharmaceuticals will report its Q1 2022 financial results during a conference call on May 10, 2022.

When will Atea Pharmaceuticals hold its earnings call?

The earnings call is scheduled for May 10, 2022, at 8:00 a.m. ET.

How can I access the Atea Pharmaceuticals earnings call?

You can access the earnings call by dialing (800) 343-5172 domestically or (203) 518-9814 internationally with conference ID AVIRQ122.

What is Atea Pharmaceuticals' focus in drug development?

Atea Pharmaceuticals focuses on developing oral therapies targeting life-threatening viral diseases, including COVID-19 and hepatitis C.